Your browser doesn't support javascript.
loading
Anaplastic Thyroid Carcinoma, Version 2.2015.
Haddad, Robert I; Lydiatt, William M; Ball, Douglas W; Busaidy, Naifa Lamki; Byrd, David; Callender, Glenda; Dickson, Paxton; Duh, Quan-Yang; Ehya, Hormoz; Haymart, Megan; Hoh, Carl; Hunt, Jason P; Iagaru, Andrei; Kandeel, Fouad; Kopp, Peter; Lamonica, Dominick M; McCaffrey, Judith C; Moley, Jeffrey F; Parks, Lee; Raeburn, Christopher D; Ridge, John A; Ringel, Matthew D; Scheri, Randall P; Shah, Jatin P; Smallridge, Robert C; Sturgeon, Cord; Wang, Thomas N; Wirth, Lori J; Hoffmann, Karin G; Hughes, Miranda.
J Natl Compr Canc Netw ; 13(9): 1140-50, 2015 Sep.
Article em En | MEDLINE | ID: mdl-26358798
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Carcinoma Anaplásico da Tireoide Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Carcinoma Anaplásico da Tireoide Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article